Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
RESEARCH TOOLSreports
Arvinas Holding Company (ARVN) Stock Price & Analysis
753 Followers
ARVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.57 - $53.08
Previous Close$33.45
Volume493.48K
Average Volume (3M)743.97K
Market Cap
$2.33B
Enterprise Value$1.02B
Total Cash (Recent Filing)$1.26B
Total Debt (Recent Filing)$3.20M
Price to Earnings (P/E)-5.1
Beta1.73
Next Earnings
Apr 30, 2024EPS Estimate
-$1.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.50
Shares Outstanding68,083,928
10 Day Avg. Volume594,298
30 Day Avg. Volume743,972
Standard Deviation0.39
R-Squared0.07
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.45
Price to Sales (P/S)-52.84
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.99
Enterprise Value/Gross Profit12.99
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$66.92Price Target Upside95.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Arvinas Holding Company News
PremiumCompany Announcements
Arvinas Partners with Novartis on Prostate Cancer Therapy
PremiumCompany Announcements
Arvinas Appoints New Chief Medical Officer for Clinical ProgramsBulls Say, Bears Say
Bulls Say
Licensing Agreement & Financial ImpactArvinas enters a lucrative licensing agreement with Novartis for ARV-766, which includes a substantial upfront payment and the promise of future milestones and royalties, enhancing the company's financial stability.
Market Expansion PotentialARV-766's potential efficacy in a broader range of AR mutations could significantly increase its addressable patient population, offering a substantial growth opportunity for Arvinas.
Strategic CollaborationThe partnership with Novartis not only provides Arvinas with essential funding to advance its Phase 3 studies but also reaffirms the innovative nature of its PROTAC platform in targeted oncology.
Bears Say
Clinical Trial ConcernsThere is uncertainty in trial timing due to the event-driven primary endpoint of VERITAC-2, although enrollment is on track.
Competitive ThreatsCompetitor data in 2024 could impact ARVN's market position, with LLY's imlunestrant presenting potential competition.
Drug Efficacy DebateInvestor debate on the read-through of the efficacy data to the ongoing Phase III trial 'VERITAC-3' due to a lower starting dose of palbociclib.
---
Ownership Overview
20.70% Insiders
26.84% Mutual Funds
15.11% Other Institutional Investors
37.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $13.57 and its highest was $53.08 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Currently, no data Available
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Apr 30, 2024 which is in 11 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Feb 27, 2024. The company reported -$2.53 earnings per share for the quarter, missing the consensus estimate of -$1.189 by -$1.341.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -$1.4.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 68,083,930 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$2.53 in its last earnings report, missing expectations of -$1.189. Following the earnings report the stock price went down -1.599%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Among the largest hedge funds holding Arvinas Holding Company’s share is New Leaf Venture Partners, L.L.C.. It holds Arvinas Holding Company’s shares valued at 53M.
---
Arvinas Holding Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.92 (95.73% Upside)
$66.92 (95.73% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 889.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $484.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 11.5%
Last 30 Days ▼ 11.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.82%
12-Months-Change
Fundamentals
Return on Equity
-59.97%
Trailing 12-Months
Asset Growth
2.82%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
---
ARVN Stock 12 Months Forecast
Average Price Target
$66.92
▲(95.73% Upside)
Technical Analysis
Best Analysts Covering ARVN
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+26.12%
reiterated a buy rating 8 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +26.12% per trade.
---